H.C. Wainwright analyst Joseph Pantginis maintained a Buy rating on Tenaya Therapeutics today and set a price target of $5.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Joseph Pantginis has given his Buy rating due to a combination of factors surrounding Tenaya Therapeutics’ innovative approaches in cardiac gene therapy. The company is making significant strides in addressing the challenges of measuring protein expression, a crucial early indicator of success in gene therapy for cardiomyopathies. Their development of two AAV-based gene therapies, TN-201 and TN-401, aims to tackle genetic causes of heart diseases by restoring functional protein levels, which could potentially halt disease progression and improve patient symptoms.
Tenaya’s collaboration with experts to develop a sensitive assay for quantifying therapeutic proteins from cardiac biopsies further strengthens their position. By employing advanced techniques like LC-MS for peptide-based normalization, they are overcoming hurdles related to sample variability and size. This comprehensive approach, which includes proteomics, imaging, and functional assays, provides a robust framework for clinical validation, supporting Pantginis’s confidence in the company’s potential for success.
According to TipRanks, Pantginis is an analyst with an average return of -7.9% and a 39.80% success rate. Pantginis covers the Healthcare sector, focusing on stocks such as Krystal Biotech, Capricor Therapeutics, and aTyr Pharma.